[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574860":3},{"organization":4,"outcomesModule":7,"designInfo":40,"detailedDescription":11,"studyPopulation":11,"armGroups":46,"interventions":76,"overallOfficials":100,"centralContacts":103,"locations":111,"responsibleParty":217,"collaborators":11,"id":219,"slug":11,"hasResults":220,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":11,"eligibilityCriteria":224,"healthyVolunteers":220,"sex":225,"minAge":226,"maxAge":11,"enrollmentInfo":227,"targetDuration":11,"studyType":230,"phases":231,"briefSummary":233,"conditions":234,"keywords":236,"overallStatus":114,"whyStopped":11,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":256},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":23,"otherOutcomes":11},[9,13,15,18,20],{"measure":10,"description":11,"timeFrame":12},"Number of participants with Adverse Events (AEs)",null,"Until the end of the Safety Follow-up period (up to approximately 100 days after last dose)",{"measure":14,"description":11,"timeFrame":12},"Number of participants with Serious AEs (SAEs)",{"measure":16,"description":11,"timeFrame":17},"Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria","From first dose of study treatment until end of cycle 1 (1 Cycle = 28 Days)",{"measure":19,"description":11,"timeFrame":12},"Number of participants with AEs leading to discontinuation",{"measure":21,"description":11,"timeFrame":22},"Number of deaths","From time of informed consent up to 52 weeks after end of treatment visit",[24,27,29,31,34,37],{"measure":25,"description":11,"timeFrame":26},"Maximum observed plasma concentration (Cmax)","Until Cycle 4, Day 1 (1 Cycle = 28 Days)",{"measure":28,"description":11,"timeFrame":26},"Time of maximum observed concentration (Tmax)",{"measure":30,"description":11,"timeFrame":26},"Area under the concentration-time curve in 1 dosing interval (AUC(TAU))",{"measure":32,"description":33,"timeFrame":22},"Objective response rate (ORR)","Defined as the proportion of participants who achieve a best overall response (BOR) of complete response (CR) or partial response (PR) assessed by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)",{"measure":35,"description":36,"timeFrame":22},"Disease control rate (DCR)","Defined as the proportion of participants who achieve a best response of CR, PR, or stable disease (SD) assessed by the investigator using RECIST v1.1",{"measure":38,"description":39,"timeFrame":22},"Duration of response (DOR)","Defined as the time between the date of first documented response (CR or PR) to the date of the first documented disease progression as assessed by the investigator using RECIST v1.1 or death due to any cause, whichever occurs first",{"allocation":41,"interventionModel":42,"interventionModelDescription":11,"primaryPurpose":43,"observationalModel":11,"timePerspective":11,"maskingInfo":44},"NON_RANDOMIZED","SEQUENTIAL","TREATMENT",{"masking":45,"maskingDescription":11,"whoMasked":11},"NONE",[47,52,56,60,64,67,70,73],{"label":48,"type":49,"description":11,"interventionNames":50},"Part 1A: BMS-986488 Monotherapy","EXPERIMENTAL",[51],"Drug: BMS-986488",{"label":53,"type":49,"description":11,"interventionNames":54},"Part 1B: BMS-986488 + Adagrasib",[51,55],"Drug: Adagrasib",{"label":57,"type":49,"description":11,"interventionNames":58},"Part 1C: BMS-986488 + Adagrasib + Cetuximab",[51,55,59],"Drug: Cetuximab",{"label":61,"type":49,"description":11,"interventionNames":62},"Part 1D: BMS-986488 + Nivolumab",[51,63],"Drug: Nivolumab",{"label":65,"type":49,"description":11,"interventionNames":66},"Part 2A: BMS-986488 Monotherapy",[51],{"label":68,"type":49,"description":11,"interventionNames":69},"Part 2B: BMS-986488 + Adagrasib",[51,55],{"label":71,"type":49,"description":11,"interventionNames":72},"Part 2C: BMS-986488 + Adagrasib + Cetuximab",[51,55,59],{"label":74,"type":49,"description":11,"interventionNames":75},"Part 2D: BMS-986488 + Nivolumab",[51,63],[77,82,89,94],{"type":78,"name":79,"description":80,"armGroupLabels":81,"otherNames":11},"DRUG","BMS-986488","Specified dose on specified days",[48,53,57,61,65,68,71,74],{"type":78,"name":83,"description":80,"armGroupLabels":84,"otherNames":85},"Adagrasib",[53,57,68,71],[86,87,88],"KRAZATI","BMS-986503","MRTX849",{"type":78,"name":90,"description":80,"armGroupLabels":91,"otherNames":92},"Cetuximab",[57,71],[93],"ERBITUX",{"type":78,"name":95,"description":80,"armGroupLabels":96,"otherNames":97},"Nivolumab",[61,74],[98,99],"OPDIVO","BMS-936558",[101],{"name":5,"affiliation":5,"role":102},"STUDY_DIRECTOR",[104,109],{"name":105,"role":106,"phone":107,"phoneExt":11,"email":108},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":110,"role":106,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[112,130,141,155,166,178,190,204],{"facility":113,"status":114,"city":115,"state":116,"zip":117,"country":118,"countryCode":119,"cosmosGeoPoint":120,"geoPoint":125,"contacts":126},"John Theurer Cancer Center at Hackensack University Medical Center","RECRUITING","Hackensack","New Jersey","07601","United States","US",{"type":121,"coordinates":122},"Point",[123,124],-74.04347,40.88593,{"lat":124,"lon":123},[127],{"name":128,"role":106,"phone":129,"phoneExt":11,"email":11},"Martin Gutierrez, Site 0021","551-996-5863",{"facility":131,"status":132,"city":133,"state":134,"zip":135,"country":118,"countryCode":119,"cosmosGeoPoint":136,"geoPoint":140,"contacts":11},"Local Institution - 0020","ACTIVE_NOT_RECRUITING","Allentown","Pennsylvania","18103",{"type":121,"coordinates":137},[138,139],-75.49018,40.60843,{"lat":139,"lon":138},{"facility":142,"status":114,"city":143,"state":144,"zip":145,"country":118,"countryCode":119,"cosmosGeoPoint":146,"geoPoint":150,"contacts":151},"The West Clinic, PLLC dba West Cancer Center","Germantown","Tennessee","38138",{"type":121,"coordinates":147},[148,149],-89.81009,35.08676,{"lat":149,"lon":148},[152],{"name":153,"role":106,"phone":154,"phoneExt":11,"email":11},"Daniel Vaena, Site 0024","901-598-1454",{"facility":156,"status":157,"city":158,"state":159,"zip":160,"country":118,"countryCode":119,"cosmosGeoPoint":161,"geoPoint":165,"contacts":11},"Local Institution - 0025","WITHDRAWN","Dallas","Texas","75390",{"type":121,"coordinates":162},[163,164],-96.80667,32.78306,{"lat":164,"lon":163},{"facility":167,"status":132,"city":168,"state":169,"zip":170,"country":171,"countryCode":172,"cosmosGeoPoint":173,"geoPoint":177,"contacts":11},"Local Institution - 0031","Brisbane","Queensland","4029","Australia","AU",{"type":121,"coordinates":174},[175,176],153.02809,-27.46794,{"lat":176,"lon":175},{"facility":179,"status":132,"city":180,"state":181,"zip":182,"country":183,"countryCode":184,"cosmosGeoPoint":185,"geoPoint":189,"contacts":11},"Local Institution - 0032","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":121,"coordinates":186},[187,188],-123.11934,49.24966,{"lat":188,"lon":187},{"facility":191,"status":192,"city":193,"state":194,"zip":195,"country":183,"countryCode":184,"cosmosGeoPoint":196,"geoPoint":200,"contacts":201},"Local Institution - 0015","NOT_YET_RECRUITING","Montreal","Quebec","H2X 0A9",{"type":121,"coordinates":197},[198,199],-73.58781,45.50884,{"lat":199,"lon":198},[202],{"name":203,"role":106,"phone":11,"phoneExt":11,"email":11},"Site 0015",{"facility":205,"status":114,"city":206,"state":194,"zip":207,"country":183,"countryCode":184,"cosmosGeoPoint":208,"geoPoint":212,"contacts":213},"Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus","Québec","G1J 1Z4",{"type":121,"coordinates":209},[210,211],-71.21454,46.81228,{"lat":211,"lon":210},[214],{"name":215,"role":106,"phone":216,"phoneExt":11,"email":11},"Antoine Morin Coulombe, Site 0016","4185254444",{"type":218,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100574860",false,"NCT06764771","A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","A Phase 1\u002F1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Participant must be ≥ 18 years of age.\n* Histologically confirmed diagnosis of a locally advanced and unresectable or metastatic solid tumor malignancy with any of the following tumor types:.\n* Part 1A: clear-cell renal cell carcinoma (ccRCC), clear-cell ovarian cancer (ccOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic ductal adenocarcinoma (PDAC).\n* Parts 2A, 1D, 2D: ccRCC.\n\n  i) Part 1B: solid tumors with KRAS G12C mutation.\n\nii) Part 2B: NSCLC with KRAS G12C mutation.\n\niii) Parts 1C, 2C: colorectal cancer (CRC) with KRAS G12C mutation.\n\n* Participants must have an Eastern Cooperative Oncology Groups (ECOG) Performance Status of 0 or 1.\n* Participants must have measurable disease per RECIST v1.1.\n\nExclusion Criteria:\n\n* Untreated central nervous system (CNS) metastases.\n* Leptomeningeal metastasis (carcinomatous meningitis).\n* Impaired cardiac function or clinically significant cardiac disease.\n* For Parts 1B, 1C, 2B, 2C only (combination with adagrasib):.\n\n  i) History of pneumonitis or interstitial lung disease (ILD).\n\nii) History of prior severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).\n\n\\- Other protocol-defined inclusion\u002Fexclusion criteria apply.","ALL","18 Years",{"count":228,"type":229},437,"ESTIMATED","INTERVENTIONAL",[232],"PHASE1","This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.",[235],"Advanced Malignant Tumors",[237,238,239,240,241,242,243,244,245,246],"Colorectal Cancer","CRC","Renal Cell Carcinoma","RCC","Non-Small Cell Lung Cancer","NSCLC","Cancer","Oncology","Phase 1","Solid Tumor","2026-07-01",{"date":249,"type":250},"2026-07-02","ACTUAL",{"date":252,"type":250},"2025-03-25",{"date":254,"type":229},"2027-10-15",{"name":5,"class":6},8]